Autologous Cord Blood Cells for Brain Injury in Term Newborns
1 other identifier
interventional
2
1 country
3
Brief Summary
This is a pilot study to test feasibility and safety of collection, preparation and infusion of a baby's own (autologous) umbilical cord blood during the first 3 days of age if the baby is born with signs of brain injury. The cord blood used is fresh (not frozen and then thawed).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_1
Started Sep 2011
Longer than P75 for phase_1
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2011
CompletedFirst Submitted
Initial submission to the registry
July 23, 2012
CompletedFirst Posted
Study publicly available on registry
July 25, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2015
CompletedJanuary 26, 2017
April 1, 2012
2.2 years
July 23, 2012
January 25, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Safety
Adverse event rates occurring in the recipients
1-3 days of age
Secondary Outcomes (2)
Neurodevelopment
1 month-2 years old
Brain imaging
1 week-6 months
Study Arms (1)
Intervention
EXPERIMENTALAutologous cord blood cells arm
Interventions
Eligibility Criteria
You may qualify if:
- Autologous umbilical cord blood available
- \>36 weeks gestation
- Brain injury that satisfies criteria for therapeutic hypothermia
- Parental informed consent
You may not qualify if:
- Inability to enroll by 3 postnatal days of age.
- Presence of known chromosomal anomaly.
- Presence of major congenital anomalies.
- Severe intrauterine growth restriction
- Infants in extremis for whom no additional intensive therapy will be offered by attending neonatologist.
- Parents refuse consent.
- Attending neonatologist refuses consent.
- Failure to collect the infant's cord blood and/or laboratory unable to process cord blood
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (3)
National University Hospital
Singapore, 119074, Singapore
KK Women's and Children's Hospital
Singapore, Singapore
Singapore General Hospital
Singapore, Singapore
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jiun Lee, MBBS
National University Hospital, Singapore
- PRINCIPAL INVESTIGATOR
Samuel Rajadurai, MBBS
KK Women's and Children's Hospital
- PRINCIPAL INVESTIGATOR
Cheo Lian Yeo, MBBS
Singapore General Hospital
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 23, 2012
First Posted
July 25, 2012
Study Start
September 1, 2011
Primary Completion
November 1, 2013
Study Completion
November 1, 2015
Last Updated
January 26, 2017
Record last verified: 2012-04
Data Sharing
- IPD Sharing
- Will not share